

Serial No. 10/687,712

Remarks

Status of the Claim:

Claims 1-25 were originally submitted and were cancelled and claims 26-32 were introduced by Preliminary Amendment filed October 10, 2003 and June 29, 2004.

Reconsideration and allowance of claims 26-32 is hereby respectfully requested in light of the following Remarks.

Double Patenting


Claims 26-32 stand rejected under the judicially created doctrine of obviousness-type double patenting over claim 13 of US Patent No. 6,664,262. To expedite the prosecution of this application and not wishing to agree on the substantive basis of the Examiner's rejection, Applicant submits hereinwith a Terminal Disclaimer in compliance with 37 CFR §1.321(c) to overcome this rejection.

Conclusion

Withdrawal of this rejection and allowance of the present application is respectfully requested. The Examiner can reach the undersigned at (914) 345-9001, Ext. 6858 when he takes this application up for further action.

February 1, 2005

Respectfully submitted,

Signed: 
By: Siu K. Lo, Esq., 46,877
TARO PHARMACEUTICALS U.S.A., INC.
Three Skyline Drive
Hawthorne, New York 10532